KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

businesswire

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema – NEWSnet – News… as it used to be

More Press Releases

Featured image for Auto-prepared featured image

May 2, 2026

Zuztec Media Highlights Areej Shaikh’s Contribution Across Sales, Content Strategy, Editing, and Digital Operations

May 2, 2026

Zuztec Media Outlines Seven-Step Digital PR Backlink Strategy for Search Visibility and Brand Authority

May 2, 2026

Theo, the Audio-First Faith App for Kids, Surpasses 5.1 Million Bible Stories and Prayers Played

May 2, 2026

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

Zuztec Media Highlights Areej Shaikh’s Contribution Across Sales, Content Strategy, Editing, and Digital Operations

Zuztec Media Outlines Seven-Step Digital PR Backlink Strategy for Search Visibility and Brand Authority

Theo, the Audio-First Faith App for Kids, Surpasses 5.1 Million Bible Stories and Prayers Played

Maverick Brands, One of America’s Top Digital Capital Raising Firms, Deploys Proprietary AI Stack for Issuers